David F. Jarrard, MD Print Friendly PageFaculty, University of Wisconsin School of Medicine and Public Health
Dr. Jarrard is board certified by the American Board of Urology and has completed a fellowship in Urologic Oncology. He specializes in all aspects of urologic oncology with an emphasis on prostate cancer diagnosis and treatment. Dr. Jarrard is also involved with surgical treatments for prostate cancer, such as the robotic prostatectomy.
UW Health Clinics
UW School of Medicine and Public Health
|Department of Urology|
Professional Certifications and Education
Urologic Oncology, Johns Hopkins Hospital, Baltimore, MD
University of Chicago Medical Center, Chicago, IL
University of Chicago Medical Center, Chicago, IL
University of Virginia School of Medicine, Charlottesville, VA, 1989
|Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.|
Our doctors provide a wide range of services. The following list represents some, but not all, of the procedures offered by this physician.
Dr. Jarrard has a joint appointment with the University of Wisconsin Carbone Cancer Center, and his clinical research emphasizes developing new therapies for genitourinary cancers. He has an active basic science laboratory and is funded through the National Institutes of Health to examine genetic and epigenetic alterations in prostate cancer.
Blute ML Jr Kucherov V Rushmer TJ Damodaran S Shi F Abel EJ Jarrard DF Richards KA Messing EM Downs TM .
Reduced estimated glomerular filtration rate (eGFR <60 mL/min/1.73 m2 ) at first transurethral resection of bladder tumour is a significant predictor of subsequent recurrence and progression. BJU Int. 2017 Sep;120(3):387-393
[PubMed ID: 28464520]
Damaschke N Yang B Bhusari S Avilla M Zhong W Blute ML Huang W Jarrard DF .
Loss of IGF2 gene imprinting in murine prostate promotes widespread neoplastic growth. Cancer Res. 2017 Aug 3;
[PubMed ID: 28775169]
Maciolek KA Jarrard DF Abel EJ Best SL .
Systematic Assessment Reveals Lack of Understandability for Prostate Biopsy Online Patient Education Materials. Urology. 2017 Aug 2;
[PubMed ID: 28780302]
Wang JH Downs TM Jason Abel E Richards KA Jarrard DF .
Prostate Biopsy in Active Surveillance Protocols: Immediate Re-biopsy and Timing of Subsequent Biopsies. Curr Urol Rep. 2017 Jul;18(7):48
[PubMed ID: 28589399]
Tazeh NN Canter DJ Damodaran S Rushmer T Richards KA Abel EJ Jarrard DF Downs TM .
Neutrophil to Lymphocyte Ratio (NLR) at the Time of Transurethral Resection of Bladder Tumor: A Large Retrospective Study and Analysis of Racial Differences. Bladder Cancer. 2017 Apr 27;3(2):89-94
[PubMed ID: 28516153]
Blute ML Jr Damaschke N Wagner J Yang B Gleave M Fazli L Shi F Abel EJ Downs TM Huang W Jarrard DF .
Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapy. PLoS One. 2017;12(2):e0172048
[PubMed ID: 28234906]
Blute ML Jr Ziemlewicz TJ Lang JM Kyriakopoulos C Jarrard DF Downs TM Grimes M Shi F Mann MA Abel EJ .
Metastatic Tumor Burden Does Not Predict Overall Survival Following Cytoreductive Nephrectomy for Renal Cell Carcinoma: a Novel 3-Dimensional Volumetric Analysis. Urology. 2017 Feb;100:139-144
[PubMed ID: 27667156]
Heninger E Krueger TE Thiede SM Sperger JM Byers BL Kircher MR Kosoff D Yang B Jarrard DF McNeel DG Lang JM .
Inducible expression of cancer-testis antigens in human prostate cancer. Oncotarget. 2016 Dec 20;7(51):84359-84374
[PubMed ID: 27769045]
Grimes MD Blute ML Jr Wittmann TA Mann MA Zorn K Downs TM Shi F Jarrard DF Best SL Richards KA Nakada SY Abel EJ .
A Critical Analysis of Perioperative Outcomes in Morbidly Obese Patients Following Renal Mass Surgery. Urology. 2016 Oct;96:93-98
[PubMed ID: 27339026]
Jarrard D Konety B Huang W Downs T Kolesar J Kim KM Havighurst T Slaton J House MG Parnes HL Bailey HH .
Phase IIa, randomized placebo-controlled trial of single high dose cholecalciferol (vitamin D3) and daily Genistein (G-2535) versus double placebo in men with early stage prostate cancer undergoing prostatectomy. Am J Clin Exp Urol. 2016;4(2):17-27
[PubMed ID: 27766277]
Blute ML Jr Zorn K Grimes M Shi F Downs TM Jarrard DF Best SL Richards K Nakada SY Abel EJ .
Extreme obesity does not predict poor cancer outcomes after surgery for renal cell cancer. BJU Int. 2016 Sep;118(3):399-407
[PubMed ID: 26589741]
Gee JR Saltzstein DR Messing E Kim K Kolesar J Huang W Havighurst TC Harris L Wollmer BW Jarrard D House M Parnes H Bailey HH .
Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomy. Eur J Cancer Prev. 2016 Jul;25(4):312-20
[PubMed ID: 26313229]
Jarrard DF Huang W .
The New Age of Molecular Taxonomy Approaches. Eur Urol. 2016 Apr;69(4):561-2
[PubMed ID: 26626616]
Kelcz F Jarrard DF .
Prostate cancer: The applicability of textural analysis of MRI for grading. Nat Rev Urol. 2016 Apr;13(4):185-6
[PubMed ID: 26878802]
Blute ML Jr Rushmer TJ Shi F Fuller BJ Abel EJ Jarrard DF Downs TM .
Renin-Angiotensin Inhibitors Decrease Recurrence after Transurethral Resection of Bladder Tumor in Patients with Nonmuscle Invasive Bladder Cancer. J Urol. 2015 Nov;194(5):1214-9
[PubMed ID: 26173101]
Abel EJ Heckman JE Hinshaw L Best S Lubner M Jarrard DF Downs TM Nakada SY Lee FT Jr Huang W Ziemlewicz T .
Multi-Quadrant Biopsy Technique Improves Diagnostic Ability in Large Heterogeneous Renal Masses. J Urol. 2015 Oct;194(4):886-91
[PubMed ID: 25837535]
Sweeney CJ Chen YH Carducci M Liu G Jarrard DF Eisenberger M Wong YN Hahn N Kohli M Cooney MM Dreicer R Vogelzang NJ Picus J Shevrin D Hussain M Garcia JA DiPaola RS .
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015 Aug 20;373(8):737-46
[PubMed ID: 26244877]
Blute ML Jr Abel EJ Downs TM Kelcz F Jarrard DF .
Addressing the need for repeat prostate biopsy: new technology and approaches. Nat Rev Urol. 2015 Aug;12(8):435-44
[PubMed ID: 26171803]
Yang B Damaschke N Yao T McCormick J Wagner J Jarrard D .
Pyrosequencing for accurate imprinted allele expression analysis. J Cell Biochem. 2015 Jul;116(7):1165-70
[PubMed ID: 25581900]
Wagner J Damaschke N Yang B Truong M Guenther C McCormick J Huang W Jarrard D .
Overexpression of the novel senescence marker β-galactosidase (GLB1) in prostate cancer predicts reduced PSA recurrence. PLoS One. 2015;10(4):e0124366
[PubMed ID: 25876105]